Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Vorinostat in Stage IV NSCLC
NCT02638090Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2016
- Primary completion
- Jan 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vorinostat in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Mar 2016; status: active, not recruiting.
02
Drugs
vorinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02638090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638090.